Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.635 +0.385 (+5.31%)
Streaming Delayed Price Updated: 12:36 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue
Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall... 
Via Finterra
Topics Economy World Trade
News headline image
Why ImmunityBio Stock Slumped on Monday ↗
The FDA isn't happy about how the biotech wanted to promote its cancer drug. 
Via The Motley Fool
News headline image
Why Are ImmunityBio Shares Rising Today? ↗
Shares of ImmunityBio, Inc. (NASDAQ: IBRX) are lifting after the company announced it secured $75 million in non-dilutive financing. 
Via Benzinga
News headline image
Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on Markets ↗
On March 24, 2026, choppy, oil-driven trading and fresh AI disruption fears pressured major U.S. indexes. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
Most active stocks in Tuesday's session ↗
Via Chartmill
News headline image
Why ImmunityBio Stock Is Down More Than 20% Today ↗
Perhaps the company's management will be more careful after a third regulatory run-in. 
Via The Motley Fool
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
ImmunityBio Crashes On FDA Warning Over Anktiva Claims ↗
ImmunityBio, Inc. (NASDAQ: IBRX) shares are trading lower after the FDA issued a warning to the company over misleading Anktiva promotions. 
Via Benzinga
News headline image
Why ImmunityBio Stock Is Up More Than 11% Today ↗
The young biopharma outfit's growth potential continues to expand. 
Via The Motley Fool
News headline image
Why Did IBRX Stock Jump 7% In Pre-Market Today? ↗
The NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA for more patients. This move broadens its potential use, though the indication is still not FDA-approved. 
Via Stocktwits
News headline image
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗
Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement. 
Via Stocktwits
Topics ETFs
News headline image
IBRX Stock Rises 3% Pre-Market: ImmunityBio Reports Breakthrough In NK Cell Therapy Production ↗
ImmunityBio also completed a Phase 1 study combining its memory cytokine-enhanced NK cell therapy with ANKTIVA. 
Via Stocktwits
News headline image
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact ↗
The company expects global expansion to drive “substantial” revenue starting in 2027. 
Via Stocktwits
News headline image
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
Via MarketBeat
News headline image
IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst ↗
The project relies on an AI-driven manufacturing robot, Leonardo, to automate production and potentially scale NK cell output. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗
ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease. 
Via Stocktwits
News headline image
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews ↗
The founder cited remarks from a former FDA official and an NIH Director supporting mechanism-based review to speed patient access to therapies like Anktiva. 
Via Stocktwits
News headline image
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva ↗
Investors are focused on Anktiva’s next regulatory step, as ImmunityBio seeks to expand the therapy to BCG-unresponsive papillary bladder cancer. 
Via Stocktwits
News headline image
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗
Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility. 
Via The Motley Fool
News headline image
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases. 
Via Stocktwits
News headline image
IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗
Piper Sandler raised the firm's price target on ImmunityBio to $12 from $7 and kept an ‘Overweight’ rating on the shares. 
Via Stocktwits
Topics Intellectual Property
News headline image
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise... 
Via MarketMinute
Topics Earnings Economy
News headline image
Dow, S&P 500, Nasdaq Futures Slip As Middle East War Fuels Oil Rally: Why MU, IBRX, BATL, DJT, SE Are On Traders’ Radar Today ↗
Investors are looking at earnings from Abercrombie & Fitch, Broadcom and Okta on Wednesday. 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗
To address the BCG shortage, ImmunityBio highlighted its recombinant BCG program, with 580 patients enrolled across about 100 clinical sites. 
Via Stocktwits
Topics Earnings Supply Chain
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗
Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds ↗
Founder Patrick Soon-Shiong is set for back-to-back prime-time interviews on Fox News and NewsNation on Friday. 
Via Stocktwits
Topics Government
News headline image
IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗
The company said it plans to submit a biologics license application by the fourth quarter of 2026. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗
Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally ↗
The filing comes ahead of ImmunityBio’s participation in the ASCO Genitourinary Cancers Symposium. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.